ArticleBMC cancer2025
Inhibition of c-Abl suppresses the proliferation, invasion and migration of glioma cells.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Demonstrating the Absence of Correlation Between Molecular Docking and in vitro Cytotoxicity in Anti-Breast Cancer Research: Root Causes and Practical Resolutions.Breast cancer (Dove Medical Press) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proto-oncogene c-Abl has been implicated in tumor progression across multiple cancer types, but its role in glioma remains poorly understood. This study aimed to investigate the function of c-Abl in glioma progression and assess its potential as a therapeutic target.
methodsHigh-throughput RNA sequencing was conducted on U-87 glioma cells following c-Abl knockdown. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore the biological pathways involved. Functional assays, including MTS for cell viability, Transwell assays for invasion and migration, and immunofluorescence (IF), were performed to evaluate cellular behavior in vitro. In vivo, a mouse xenograft model was treated with the c-Abl inhibitor dasatinib, and tumor progression was assessed by hematoxylin and eosin (HE) and immunohistochemistry (IHC) staining.
resultsRNA sequencing revealed that differentially expressed genes (DEGs) following c-Abl knockdown were significantly enriched in cell cycle-related pathways. Silencing c-Abl reduced U-87 cell viability by 7% at 48 h and 15.3% at 72 h (P < 0.01 and P < 0.0001) and suppressed cell invasion and migration by 48.3% and 40.6%, respectively (P < 0.001). Knockdown also reduced expression of Ki67, Snail, and Vimentin. In vivo, dasatinib treatment decreased tumor volume by 51.8% by day 24 (P < 0.001), increased necrotic area (P < 0.01), and downregulated epithelial-mesenchymal transition (EMT) markers (P < 0.05).
conclusionsc-Abl contributes to glioma cell proliferation, invasion, and migration, likely through pathways related to cell cycle and EMT. These findings support c-Abl as a promising therapeutic target in glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.